Vanberra Signal

BioImagene

Curated by Signal

Digital Pathology for clinical diagnostics and drug discovery

Overview

Digital Pathology for clinical diagnostics and drug discovery The company offers IHC algorithms, such as HER2, ER/PR, and p53 for breast cancer; Ki67 for breast, brain, and prostate cancers; CD138 for multiple myeloma; CD3/CD20 for lymphoma; iSlide input device, a device that allows pathologists to use a microscope interface to manipulate digital images of slides; and iScan Coreo Au digital slide scanners that enable digital pathology applications, such as image analysis, telepathology, remote microscopy, and education.

Key facts

Founded
2003

Contact

More on Vanberra Signal

Members only

Competitors & similar companies

More Life Sciences Technology companies
  • Developer of non-invasive postpartum hemorrhage detection device

    Life Sciences TechnologyAustin, United States
  • Developer of a diagnostic device for skin cancer

    Life Sciences TechnologyMiami, United States
  • Provider of hemp-based gauze for wound care

    Life Sciences TechnologyBurlington, United States

About BioImagene

What does BioImagene do?

Digital Pathology for clinical diagnostics and drug discovery The company offers IHC algorithms, such as HER2, ER/PR, and p53 for breast cancer; Ki67 for breast, brain, and prostate cancers; CD138 for multiple myeloma; CD3/CD20 for lymphoma; iSlide input device, a device that allows pathologists to use a microscope interface to manipulate digital images of slides; and iScan Coreo Au digital slide scanners that enable digital pathology applications, such as image analysis, telepathology, remote microscopy, and education.

Where is BioImagene headquartered?

BioImagene is headquartered in Sunnyvale, United States.

When was BioImagene founded?

BioImagene was founded in 2003.

Which sector is BioImagene in?

BioImagene operates in Life Sciences Technology.

Who are BioImagene's competitors?

Companies similar to BioImagene include Hemorai, DermaSensor, and EcoGauze.